---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-000752"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:33:39.293191+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response

## Summary
- Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.
- Cash $319.7M at March 31, 2022; expected to fund operations into late 2023.
- ARCT-154 booster data: 54-fold and 46-fold GMFR against Omicron BA.1 and BA.2 at Day 29.
- Primary vaccine efficacy 95.3% against severe COVID-19; 55% overall; 98.4% seroconversion.
- ARCT-810 Phase 2 OTC deficiency trial to start Q2 2022; ARCT-032 cystic fibrosis CTA filing on track for Q3 2022.

## SEC filing metadata
- accession: 0001193805-22-000752
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/0001193805-22-000752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/e621634_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-000752
- JSON: https://secwatch.observer/filing/0001193805-22-000752.json
- Plain text: https://secwatch.observer/filing/0001193805-22-000752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.